Bioethics for clinicians: 17. Conflict of interest in research, education and patient care

CMAJ. Canadian Medical Association Journal

Volumn 159, Issue 8, 1998, Pages 960-965

  Lemmens, Trudo ^a,b   Singer, Peter A ^a,b,c,d  

^a at the University of Toronto Wagner is also a faculty member of the Canadian Medical Associations' Physician Management Institute   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c Sun Life Department in Bioethics

^d Toronto Hospital

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; DRUG INDUSTRY; FINANCE; HEALTH CARE PERSONNEL; HEALTH CARE POLICY; HUMAN; LEGAL ASPECT; MEDICAL EDUCATION; MEDICAL ETHICS; MEDICAL RESEARCH; PATIENT CARE;

EID: 0032552857     PISSN: 08203946     EISSN: 14882329     Source Type: Journal    
DOI: None     Document Type: Article

References (36)

1. Thompson DF. Understanding financial conflicts of interest. N Engl J Med 1993;329:573-6.
2. Cohen L. Issue of fraud raised as MD self-referral comes under spotlight in Ontario. CMAJ 1996;154(11):1744-6.
3. Chren MM, Landefeld CS, Murray TH. Doctors, drug companies, and gifts. JAMA 1989;262(24):3448-51.
4. Hodgkinson v. Simms (1994) 117 DLR (4th) 161, 178-9 (C).
5. Dickens B. Conflicts of interest in Canadian health care law. Am J Law Med 1995;21:259-80.
6. SO 1991 c 18, cl 51(1)(c).
7. Cox v. College of Optometrists of Ontario (1988) 65 OR (2d) 461 (Ont Div Ct).
8. Avorn J, Chen M, Hartley R. Scientific versus commercial sources of influence on the prescribing behavior of physicians. Am J Med 1982;73:4-8.
9. Relman AS. Dealing with conflicts of interest. N Engl J Med 1985;313:749-51.
10. Relman AS. New "information for authors" - and readers. N Engl J Med 1990;323:56.
11. American College of Physicians. Physicians and the pharmaceutical industry [position paper]. Ann Intern Med 1990;112:624-6.
12. Council on Ethical and Judicial Affairs. Gifts to physicians from the industry (opinion 8.061 of Dec. 3, 1990). JAMA 1991;265:501.
13. Canadian Medical Association. Physicians and the pharmaceutical industry (update 1994) [policy summary]. CMAJ 1994;150(2):256A-C.
14. Education Council, Residency Training Programme in Internal Medicine, Department of Medicine, McMaster University. Development of residency program guidelines for interaction with the pharmaceutical industry. CMAJ 1993;149(4):405-8.
15. Guyatt G. Academic medicine and the pharmaceutical industry: a cautionary tale. CMAJ 1994;150(6):951-3.
16. Forrest JB. Faculties of health sciences and the pharmaceutical industry: an effective partnership. CMAJ 1994;151(9):1320-2.
17. Arkinstall WW. Interaction between physicians and the pharmaceutical industry [letter]. CMAJ 1995;153(4):398-9.
18. Pharmaceutical Manufacturers Association of Canada. Code of Marketing Practices. Ottawa: The Association; 1994.
19. Lexchin J. Enforcement of codes governing pharmaceutical promotion: What happens when companies breach advertising guidelines? CMAJ 1997; 156(3):351-6.
20. Desjardins JG. The PMAC Code of Marketing Practices: Time for improvement? CMAJ 1997;156(3):363-4.
21. Lexchin J. Interactions between physicians and the pharmaceutical industry: What does the literature say? CMAJ 1993;149(10):1401-7.
22. Hodges B. Interactions with the pharmaceutical industry: experiences and attitudes of psychiatry residents, interns and clerks. CMAJ 1995;153(5):553-9.
23. Sergeant MD, Hodgetts G, Godwin M, Walker DMC, McHenry P. Interactions with the pharmaceutical industry: a survey of family medicine residents in Ontario. CMAJ 1996;155(9):1243-8.
24. Campbell EG, Louis KS, Blumenthal D. Looking a gift horse in the mouth: corporate gifts supporting life sciences research. JAMA 1998;279(13):995-9.
25. Davidson RA. Source of funding and outcome of clinical trials. J Gen Intern Med 1986;1:155-8.
26. Stelfox HT, Chua G, O'Rourke K, Detsky AS. Conflict of interest in the debate over calcium-channel antagonists. N Engl J Med 1998;338:101-6.
27. Randall T. AMA, Pharmaceutical Association form "solid front" on gift-giving guidelines. JAMA 1991;265:2304-5.
28. Pushing drugs to doctors. Consum Rep 1992;Feb:87-94.
29. McKinney WP, Schiedermayer DL, Lurie N, Simpson DE, Goodman JL, Rich EC. Attitudes of internal medicine faculty and residents toward professional interaction with pharmaceutical sales representatives. JAMA 1990;264 (13):1693-7.
30. Aldir RE, Jarjoura D, Phinney M, Poordad F, Guttierez R, Marnejon T, et al. Practicing and resident physicians' views on pharmaceutical companies. J Contin Educ Health Prof 1996;16:25-31.
31. Gibbons RV, Landry FJ, Blouch DL, Jones DL, Williams FK, Lucey CR, et al. A comparison of physicians' and patients' attitudes toward pharmaceutical industry gifts. J Gen Intern Med 1998;13:151-4.
32. Kassirer JP, Angell M. Financial conflict of interest in biomedical research. N Engl J Med 1993;329:570-1.
33. Frances L. IRBs and conflicts of interest. In: Spece RG, Schimm DS, Buchanan AE, editors. Conflicts of interest in clinical practice and research. New York: Oxford University Press; 1996. p. 418-36.
34. Bero LA. Disclosure policies for gifts from industry to academic faculty [editorial]. JAMA 1998;279:1031-2.
35. Flegel KM. Physicians, finder's fees, and free, informed consent [editorial]. CMAJ 1997;157(10):1373-4.
36. Garfinkel PE, Dorian B, Sadavoy J, Bagby RM. Boundary violations and departments of psychiatry. Can J Psychiatry 1997;42:764-70.